Stock ARVN ARVINAS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-30 EDT 		5-day change 1st Jan Change
31.77 USD -0.41% Intraday chart for Arvinas, Inc. -6.56% -22.81%
04-24 Arvinas, Inc. Appoints Randy Teel as Chief Business Officer CI
04-15 H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
Novartis : accord de licence dans le cancer de la prostate
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
Novartis étend sa recherche contre le cancer de la prostate
Novartis erweitert Pipeline mit Lizenzabkommen für Prostatakrebs-Kandidaten
Novartis licenses Arvinas' cancer drug for up to $1 billion
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer
Arvinas Appoints Noah Berkowitz as Chief Medical Officer
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Arvinas, Inc. Announces Executive Changes, Effective February 29, 2024
Early-Stage Trial of Arvinas, Pfizer's Vepdegestrant Combined With Samuraciclib to Potentially Treat Metastatic Breast Cancer Gets Underway
Arvinas, Pfizer's Breast Cancer Treatment Vepdegestrant Receives FDA Fast-Track Investigation Designation
Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy
Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel
A Wall Street, record pour le Dow Jones, le S&P 500 tout près de son sommet
Arvinas Shares Climb After Wells Fargo Upgrade
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. News Arvinas, Inc.
  5. Other languages